Phase I Trial of Nedaplatin and Paclitaxel for Patients with Non-Small Cell Lung Cancer

A phase I study was conducted to evaluate the maximum tolerated dose and feasibility of combination with nedaplatin (NDP) and paclitaxel in patients with nonsmall cell lung cancer (NSCLC). Fifteen patients under 75 years old, with unresectable NSCLC who had not previously received chemotherapy or ra...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chemotherapy (Florence) 2005-10, Vol.17 (5), p.550-554
Main Authors: Yoshiike, F., Koizumi, T., Kitaguchi, Y., Hatayama, O., Yasuo, M., Sasabayashi, M., Wakamatsu, H., Fujimoto, K., Kubo, K.
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Female
Humans
Infusions, Intravenous
Lung Neoplasms - drug therapy
Male
Maximum Tolerated Dose
Middle Aged
Nedaplatin
neutropenia
new generation platinum compound
non-small cell lung cancer
Organoplatinum Compounds - administration & dosage
Paclitaxel - administration & dosage
thrombocytopenia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A phase I study was conducted to evaluate the maximum tolerated dose and feasibility of combination with nedaplatin (NDP) and paclitaxel in patients with nonsmall cell lung cancer (NSCLC). Fifteen patients under 75 years old, with unresectable NSCLC who had not previously received chemotherapy or radiotherapy, with a performance status of 0-1, were enrolled. The dose escalation levels (NDP/Paclitaxel; mg/m 2 day 1) were 80/150 (level 1), 80/180 (level 2), 90/180 (level 3) and repeated every 28 days. All patients receiving level 3 had dose-limiting toxicity. One patient developed grade 4 neutropenia with infection, two had incomplete recovery of neutropenia and thrombocytopenia by the 28th day after the first cycle of chemotherapy. Non-hematologic toxicities, including nephrotoxicity, nausea/vomiting, alopecia, and hypersensitivity reaction, were tolerated. Three of the 15 patients achieved partial responses. We concluded that the recommended dose was paclitaxel 180 and NDP 80 mg/m 2 due to the hematologic toxicity.
ISSN:1120-009X
1973-9478
DOI:10.1179/joc.2005.17.5.550